CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-15 | Kaye Edward M. MD Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +3,636 | 3,636 | ||
| 2024-05-15 | PARSHALL B LYNNE Director | Grant or award | +5,600 | 20,600 | ||
| 2024-05-15 | PARSHALL B LYNNE Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +3,636 | 3,636 | ||
| 2024-05-15 | WIERENGA WENDALL Director | Grant or award | +5,600 | 24,327 | ||
| 2024-05-15 | WIERENGA WENDALL Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +3,636 | 3,636 | ||
| 2024-05-15 | Wysenski Nancy Director | Grant or award | +5,600 | 22,756 | ||
| 2024-05-15 | Wysenski Nancy Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +3,636 | 3,636 | ||
| 2024-05-07 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +14,186 | $6.67 | $95K | 152,603 |
| 2024-05-07 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −14,186 | $65.11 | $924K | 138,417 |
| 2024-05-07 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −1,361 | $65.11 | $89K | 137,056 |
| 2024-05-07 | Malik Fady Ibraham EVP Research & Development | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −14,186 | 0 | ||
| 2024-04-25 | HENDERSON JOHN T Director | Sale 10b5-1 | −10,562 | $64.54 | $682K | 32,070 |
| 2024-04-12 | Malik Fady Ibraham EVP Research & Development | Gift | −150 | 138,417 | ||
| 2024-04-09 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +28,605 | $6.67 | $191K | 171,172 |
| 2024-04-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −28,605 | $74.31 | $2.1M | 142,567 |
| 2024-04-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −4,000 | $74.32 | $297K | 138,567 |
| 2024-04-09 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −28,605 | 0 | ||
| 2024-03-14 | Wong Robert VP, Chief Accounting Officer | Grant or award | +4,079 | 29,664 | ||
| 2024-03-14 | Wong Robert VP, Chief Accounting Officer | Grant or award · Incentive Stock Option (Right to Buy) | +1,403 | 1,403 | ||
| 2024-03-14 | Wong Robert VP, Chief Accounting Officer | Grant or award · Non-Qualified Stock Option (Right to Buy) | +3,308 | 3,308 |
Page 33 of 33 · 660 trades